Abstract
Cancer has emerged as one of the most severe diseases in modern times, various therapies have advanced remarkably in recent decades. Unlike the direct therapeutic targeting tumor cells, immunotherapy is a promising strategy that stimulate the immune system. In cancer immunotherapy, polymeric-based nanoparticles can serve as deliver systems for antigens and immunostimulatory molecules, and they have attracted increasing attention and revolutionized cancer therapy. Poly (lactic-co-glycolic acid) (PLGA) is the most frequently used clinically approved biodegradable polymer and has a broad scope of modification of its inherent properties. Recent advances in PLGA based drug delivery systems in cancer immunotherapy have been described in this mini review, with special emphasis on cancer vaccines and tumor microenvironment modulation.
Introduction
Cancer immunotherapy has received extensive attentions in the past decades, and it has been the fourth most important cancer therapy, after surgery, radiation therapy, and chemotherapy. The rational combination of cancer immunotherapy with other therapeutic modalities has gradually become an emerging therapeutic strategy (). However, mainly due to the lack of effective vectors, many pre-clinical trials have failed to progress to the clinical stage. Nanotechnology offers an opportunity to overcome these limitations. Compared to its bulk structures, nanoparticles have remarkable properties such as smaller size (1–100 nm in diameter), greater surface area to volume ratio, higher cell penetration ability, and enhanced physicochemical properties (). Due to these unique properties, nanoparticles hold great interests in various biomedical applications, and they have also been extensively used as carriers in cancer immunotherapy. As the most widely used immunostimulatory nanoparticles, polymeric nanoparticles are highly appreciated for their preeminent biocompatibility, aqueous solubility, high payload capacity, backbone stability and feasibility of modification to increase targeting ability or responsiveness ().
The widely developed polymeric nanoparticle-based delivery systems for cancer immunotherapy usually have a core–shell (also known as membrane-core) structure wherein the hydrophobic or charged polymers form the inner core, while the shell-forming polymers have neutral, hydrophilic and flexible properties for stealth nanoparticles. Based on the amphiphilic property, a variety of formulation strategies such as the oil-in-water (O/W) single emulsion process (for hydrophobic cargos) and the water-in-oil-in-water (W/O/W) double emulsion method (for hydrophilic cargos), have been used. Stimuli-responsiveness (temperature, pH, enzymatic, reductive or oxidative, etc.) can be imparted into the core, shell and/or the linkages.
PLGA (poly-D,L-lactide-co-glycolide) is one of the most successfully used biodegradable polymers for the development of nanomedicines (; ; ). Since the body effectively deals with the two biodegradable monomers of PLGA (lactic acid and glycolic acid, which can then be metabolized via the Krebs cycle yielding nontoxic byproducts H2O and CO2, see Figure 1), it shows very minimal systemic toxicity for drug delivery. A major advantage of PLGA over other polymers is that PLGA has been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for pharmaceutical applications via parenteral and mucosal routes, leading PLGA-based nanoparticles in a good position for clinical trials (; ).
FIGURE 1
Because vaccines can be easy to deploy and have historically represented an approach that has brought enormous medical benefit, therapeutic vaccines against cancer have been explored since the early discovery of tumor-specific antigens (). In the cancer-immunity cycle, cancer vaccines can primarily promote the cancer antigen presentation step () (Figure 2) to accelerating and expanding the production of T cell immunity. Although vaccine strategies for the generation of tumor-specific immunological responses continue to have great promise, they were limited on two aspects. First, a general lack of understanding of how to identify proper cancer vaccine delivery system to achieve potent cytotoxic T cell responses. Second, immunosuppressive environment within the tumor resulted in poor therapeutic outcome in clinic. Thus, in this review, we have focused on both cancer vaccines and tumor microenvironment modulation aimed at resulting in an effective systemic antitumor immunity.
FIGURE 2
Cancer vaccines
Tumor-associated antigens (TAAs), the adjuvants, and the delivery system are three essential components of therapeutic vaccine (). In cancer immunotherapy, PLGA nanoparticles have been tested as delivery systems to ameliorate the efficiencies of therapeutic vaccines. Tumor-associated antigens (TAAs), adjuvants as toll-like-receptor (TLR) agonists, and also tumor lysates have been encapsulated in PLGA nanoparticles (). In a study reported by , photothermal agent Indocyanine green (ICG), and Toll-like-receptor-7 agonist imiquimod (R837), were co-encapsulated into PLGA nanoparticles by oil-in-water (o/w) emulsion method. When the multifunctional nanoparticles were used for photothermal ablation of primary tumors, they can generate TAAs, which induce vaccine-like immune responses with R837 as the adjuvant. In combination with the checkpoint-blockade therapy using anti-cytotoxic T-lymphocyte antigen-4 (CTLA4), the generated immunological responses are able to attack the remaining tumor cells in mice, provide inhibition in metastasis and offer a strong immunological memory effect. This strategy showed that combining tumor-specific vaccines that stimulate cytotoxic T lymphocytes (CTL) responses with immune checkpoint blockade therapy is an attractive tool. Recently, developed a vaccine based on PLGA particles possess a relatively broad size distribution ranging from nanosized up to 1.5 µm sized particles. Ovalbumin (OVA) and double-stranded (ds) RNA adjuvant Riboxxim were co-encapsulated into the PLGA particles. PLGA particles induced the supreme adjuvant effect of Riboxxim, potently activated murine and human dendritic cells, and elevated tumor-specific CD8+ T cell responses. This PLGA particle vaccine delays tumor progression, suppresses tumor metastasis, and provides prolonged survival of immunized mice, and its advantageous therapeutic potency was further enhanced by immune checkpoint blockade that resulted in reinvigoration of cytotoxic T lymphocyte responses and tumor ablation.
Fast recognition and non-specific clearance of nanoparticles by innate immune system, clinical applications of nanoparticles are usually hampered. To further improve the potency, deliver more antigens to the desired site, some modifications of PLGA nanoparticle-based delivery systems were studied. To enhance antigen processing and presentation, the endosomal membrane disrupting agent hydroxychloroquine (HCQ) was encapsulated into PLGA nanoparticles with ovalbumin (OVA) (). In vitro experiments showed the nanoparticles enhanced OVA escape from the lysosome into the cytoplasm and also improved cross-presentation of antigen. In vivo studies concluded that this co-delivery nanovaccine can provide strong CD8+ T cell immune responses that induced tumor cell apoptosis and long-lasting antigen-specific memory immune responses in vaccinated mice. have developed a PLGA nanoparticle vaccine in which PLGA nanoparticle as delivery system encapsulated the antigenic peptide HPV16 E744-62 and adenosine triphosphate (ATP) as adjuvant component. Peptides were encapsulated into PLGA nanoparticles using a two-stage emulsification method, ATP was introduced by simple mixing 10 μl ATP with 90 μl of E744-62-loaded nanoparticles. Employing PLGA nanoparticles increased lymph node accumulation, and dendritic cell (DC) uptake of the E7 peptide. ATP adjuvant further increased the migration, nanoparticle uptake, and maturation of DCs. ATP-adjuvanted nanoparticles stimulated cell-mediated immune responses, completely abolished the growth of TC-1 tumors, produced long-lasting immunity and significantly delayed tumor progression in vaccinated mice.
Because of the “proton sponge” effect-induced antigen escape, cationic polymers can facilitate antigen adsorption and uptake by APCs such as DCs (). To endow the PLGA nanoparticles with positive surface charge, a relatively safe cationic surfactant dimethyl-dioctadecyl-ammonium bromide (DDAB) is chosen, and the DDAB/PLGA nanoparticles were prepared using nanoprecipitation (). The positively charged surface of the DDAB/PLGA nanoparticles enabled the negatively charged antigen of the model antigen ovalbumin (OVA257-264) to be easily absorbed to the surface via electrostatic interaction to obtain an OVA@DDAB/PLGA nanovaccine. Experiments performed in vitro revealed that the nanovaccine induced antigen escape from lysosome into cytoplasm with 10 times increased cross-presentation activity than naked OVA. The nanovaccine showed excellent draining lymph nodes (LNs) transportation ability by passive lymphatic drainage and active DC transport. After immunization, the OVA@DDAB/PLGA nanovaccine can stimulate both humoral and cell-mediated immune responses and offer a strong immunological memory effect.
Another strategy that exhibits great potential in the disease diagnosis and therapeutics is membrane coating nanotechnology (). It has revolutionized the design of cancer vaccine by endowing targeting, antigen presentation and immune stimulation. Diverse membrane coating platforms have been developed for cancer vaccine design. In a study by , TLR7 agonist imiquimod (R837) loaded PLGA nanoparticles were coated with B16-OVA cancer cell membranes, whose surface proteins could act as tumor specific antigens. The obtained nanoparticles were further modified with mannose by a lipid-anchoring method. This PLGA complex was efficiently targeted and internalized by antigen presenting cells (APCs) such as DCs, which triggered potent antitumor immunotherapeutic efficacy. designed a lipid-coated PLGA hybrid particles for the co-delivery of mRNA and TLR7 adjuvant. In this carrier system, the PLGA core enabled the efficient loading of the hydrophobic gardiquimod, and the lipid shell loaded the mRNA via electrostatic interaction. The hybrid nanovaccine led to the effective antigen expression and DC maturation in vitro, also a stronger antigen-specific immune response was obtained. The spatial/temporal overlap of the antigen and adjuvant via the core-shell nanoparticles are found to be beneficial for tumor growth inhibition. designed a nanovaccine composing of a PLGA core to encapsulate TLR7 agonist imiquimod (R837), a phospholipid membrane to load antigen peptide (αOVA) and apolipoprotein E3 (ApoE3). Incorporation of ApoE3 facilitate nanovaccines uptake through the micropinocytosis pathway, and significantly promoted DCs maturation and antigen presentation. More in vivo studies showed that these nanoparticles migrated to the lymph nodes, leading to strong T cell immune responses. The nanovaccine also provided inhibition in metastasis in lung, and exerted superior therapeutic efficiency on B16-OVA tumor-bearing mice when in combination with αPD-1 therapy. Nowadays the membrane-coated technology with membranes from different types of cells offers promising opportunities for cancer immunotherapy, cell membranes employed have gradually shifted from natural to engineered (; ). In the nanovaccine developed by , peptide CBP-12 expressed biomimetic cancer cell membrane coating strategy was adopted to specifically target Clec9a+ DCs. The membrane coated PLGA drug-delivery system efficiently delivers tumor antigen and STING agonist (cGAMP) to Clec9a+ DCs, significantly enhanced IFN-stimulated expression of genes and antigen cross-presentation of Clec9a+ DCs, eliciting strong antitumor effects in anti-PD-1-resistant tumor models without obvious cytotoxicity. Moreover, combination of the nanovaccine with radiotherapy remarkably enhances the cancer immunotherapy effects.
Tumor microenvironment modulation
The immunosuppressive tumor microenvironment consists of cells, soluble factors, signaling molecules, extracellular matrix, and mechanical cues (), it is created by the tumor and dominated by tumor-induced interactions (). Modulating the tumor microenvironment with efficient modulator will significantly promote the immune responses inside a tumor. Using nanoparticles for remodeling the tumor microenvironment is a promising immunotherapeutic strategy to overcome “immune escape” and resulting in an effective systemic antitumor immunity.
Efficient capture and presentation of tumor antigens by APCs, especially dendritic cells (DCs), are crucial for anti-tumor immunity. However, APCs are immunosuppressed in the tumor microenvironment. Kim et al. () showed that incorporating TLR 7/8 agonists into PLGA nanoparticles could significantly increase co-stimulatory molecule expression and antigen presentation in DCs compared to free agonists. In vivo studies showed that these nanoparticles migrated to the lymph nodes, triggering DC activation and expansion, leading to enhanced cytotoxic T lymphocytes (CTL) responses, and in turn, improving prophylactic and therapeutic efficacy in melanoma, bladder, and renal cell carcinoma tumor models. Later, to overcome fast clearance from the injection site, pH responsiveness is incorporated into the TLR7/8 agonist delivery platform (). Bicarbonate salt was adopted, the salt generates carbon dioxide at acidic pH, which can disrupt the polymer shell to rapidly release the payload. The acid-responsive formulation was characterized by higher drug encapsulation and DC activation leading to the expansion of activated natural killer (NK) cells and antigen-specific CD8+ T cells. Da Silva et al. () used PLGA nanoparticles as delivery vehicles for the co-delivery of three immune adjuvants [the TLR3 agonist Poly (I:C;pIC), TLR7/8 agonist Resiquimod (R848) and the chemokine Macrophage Inflammatory Protein-3 alpha (MIP3α)] to significantly improve the therapeutic efficacy of cancer vaccines. Co-delivery of these modulating agents using PLGA nanoparticles significantly potentiated the cancer vaccine antitumor effects. The long-term survival of mice with established large carcinoma tumors was improved to 75%–100%, and the progression free survival of the mice nearly doubled. The potent adjuvant effect was associated with lymphoid and myeloid cell population alterations in the tumor and tumor-draining lymph node. developed a co-delivery immunotherapeutic strategy of the phagocytosis checkpoint (signal regulatory protein α, SIRPα) silencer and stimulator of interferon genes (STING) of APCs. A small interfering RNA targeting SIRPα (siSIRPα) and a STING agonist (cGAMP) were encapsulation into PLGA-based polymeric nanoparticles using the double emulsification method. In the ovalbumin-expressing B16-F10 (OVA-B16-F10) melanoma model, NPsiSIRPa/cGAMP stimulated the activation of OVA-specific CD8+ T cells and induced holistic anti-tumor immune responses by reversing the immunosuppressive phenotype of APCs.
As effectors of innate immunity, natural killer (NK) cells represent ‘the first line’ of defense against pathogens and mediate potent antitumor cytotoxicity in vitro through secretion of cytotoxic lymphokines and disruption of the tumor vascular. Adoptive immunotherapy (AIT) with natural killer (NK) cells has emerged as a potential treatment strategy. However, their paucity in tumor infiltrates causes the low therapeutic efficacy of NK cell ATI. . demonstrate MRI-monitored transcatheter intra-arterial (IA) local delivery of IFN-γ and iron oxide nanocubes (IONC) co-encapsulated PLGA nanoparticles to induce efficient NK cells infiltration to tumor sites for the targeted treatment of liver cancer. In an orthotopic liver tumor VX2 rabbit model, the prepared nanoparticles showed a sustained IFN-γ release and highly sensitive MR T2 contrast effects, significantly increased NK-cell infiltration into the liver tumor site.
Neutrophils can exert antitumoral functions especially in early stage of tumor development. However, they have been also shown to facilitate tumorigenesis and mediate immunosuppression. Due to their innate phagocytic functions and oriented migration capabilities in response to chemoattractants, nanoparticle-loaded neutrophils were used as “Trojan horses” (). The pre-implantation of chemokine CXCL1-laden hydrogels could trigger and induce a targeted signal to attract an influx of neutrophils carrying the therapeutic goods to the desired position, thus the effectiveness of neutrophil-mediated nanoparticles drug delivery system is improved. In vivo studies showed that the combinatorial regimen of using the paclitaxel (PTX) loaded PLGA nanoparticles with the CXCL1 chemokine laden PLGA-PEG-PLGA thermosensitive hydrogels exhibited superior tumor inhibition capability in mouse models of melanoma.
Tumor-associated macrophages (TAMs) are abundant in most human and experimental murine cancers, they are the major contributors to tumor angiogenesis, and also influence lymphocyte infiltration, leading to immunosuppression (). developed an M2-like macrophage-targeting nanoparticles to switch the tumor-promoting immune suppressive microenvironment by reprogramming TAMs. In these nanoparticles resiquimod (R848, a potent driver of macrophage reprogramming) loaded PLGA nanoparticles were coated with the B16-OVA cancer cell membrane. The membrane can increase the expression of CD47, which could avoid the nanoparticles being cleared by the reticuloendothelial system. The membrane was further modified with poly (ethylene glycol) (PEG) to achieve better long blood circulation and finally modified with M2pep to improve the selectivity and specificity for M2-like macrophages. The nanoparticles provide an effective and selective reprogramming strategy for macrophage-mediated cancer immunotherapy. More in vivo studies showed that the loading nanoparticles reduced tumor size, and prolonged survival compared to the control groups.
Conclusion
This article briefly reviewed recent studies directed to improve the efficiency of PLGA-based delivery systems in cancer immunotherapy. In Table 1, we summarized these studies. Biocompatibility, biodegradability, and feasibility of modification are the most interesting features of PLGA-based nanoparticles, which can support these materials to have a good position in the development of nanomedicines. However, the high cost of production, the difficulty of the scale-up, fast in vivo degradation of non-coated nanoparticles and the relatively low drug loading efficiency are the main limitations of PLGA-based delivery systems. Although further research and clinical studies are still needed to improve the efficacy of drug delivery, the recent studies presented in this mini review clearly illustrate the promise of PLGA-based nanoparticles for novel treatments of cancer in the future.
TABLE 1
| Nanocarrier | Payload | Tumor model | Outcomes | References |
|---|---|---|---|---|
| PLGA NPs | ICG, R837 | 4T1 breast cancer, CT26 cancer | Promoted generation of TAAs | |
| PLGA NPs | OVA, Riboxxim | EG7-OVA thymoma | Induced strong anti-tumor immune response | |
| PLGA NPs | OVA, Hydroxychloroquine (HCQ) | EG7-OVA thymoma | Provided strong CD8+ T cell immune responses | |
| PLGA NPs | HPV16 E744-62, ATP | TC-1 tumor | Induced strong anti-tumor immune response | |
| DDAB/PLGA NPs | OVA | -- | Enhanced the efficiency of nanovaccine | |
| Cancer cell membrane-coated PLGA NPs | R837 | 4T1 breast cancer | Enhanced uptake of vaccine by DCs, which significantly promoted DCs maturation and antigen presentation | |
| Engineered peptide-expressed biomimetic cancer cell membrane-coated PLGA NPs | 2′3′-cGAMP | B16-OVA melanoma, 4T1 breast cancer | ||
| Lipid-coated PLGA NPs | mRNA, gardiquimod | B16-OVA melanoma | ||
| Lipid-coated PLGA NPs | R837, OVA, ApoE3 | B16-OVA melanoma | ||
| PLGA NPs | TLR7/8 agonists | Melanoma, Bladder, Renal Cell Carcinoma | Enhanced antigen specific immune response | |
| PLGA NPs | TLR7/8 agonists, NaHCO3 | Melanoma | Resulted in higher loading of payload | |
| PLGA NPs | Poly (I:C), R848, MIP3α | Carcinoma, Lymphoma | Enhanced the efficiency of nanovaccine | |
| PLGA NPs | siSIRPα, cGAMP | Melanoma | Induced strong anti-tumor immune response | |
| PLGA NPs | IFN-γ, Iron oxide nanocubes | Liver tumor | Enabled MRI-guided transcatheter IA delivery to liver tumor | |
| PLGA NPs | Paclitaxel (PTX) | Melanoma | Enhanced the tumor inhibition capability | |
| M2pep modified cancer cell membrane-coated PLGA NPs | R848 | B16-OVA melanoma | Inhibited tumor growth by reporamming TAMs |
PLGA-based nanoparticles used as delivery systems in cancer immunotherapy.
Statements
Author contributions
LG and JL designed and wrote the manuscript, designed the pictures, and critically reviewed the manuscript. LG and TS searched articles relating to the subject. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AcharyaS.SahooS. K. (2011). PLGA Nanoparticles Containing Various Anticancer Agents and Tumour Delivery by EPR Effect. Adv. Drug Deliv. Rev.63 (3), 170–183. 10.1016/j.addr.2010.10.008
2
BalkwillF. R.CapassoM.HagemannT. (2012). The Tumor Microenvironment at a Glance. J. Cell. Sci.125 (23), 5591–5596. 10.1242/jcs.116392
3
ChenDaniel S.MellmanI. (2013). Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity39 (1), 1–10. 10.1016/j.immuni.2013.07.012
4
ChenQ.HuangG.WuW.WangJ.HuJ.MaoJ.et al (2020). A Hybrid Eukaryotic–Prokaryotic Nanoplatform with Photothermal Modality for Enhanced Antitumor Vaccination. Adv. Mat.32 (16), 1908185. 10.1002/adma.201908185
5
ChenQ.XuL.LiangC.WangC.PengR.LiuZ. (2016). Photothermal Therapy with Immune-Adjuvant Nanoparticles Together with Checkpoint Blockade for Effective Cancer Immunotherapy. Nat. Commun.7 (1), 13193. 10.1038/ncomms13193
6
ChenQ.ZhangL.LiL.TanM.LiuW.LiuS.et al (2021). Cancer Cell Membrane-Coated Nanoparticles for Bimodal Imaging-Guided Photothermal Therapy and Docetaxel-Enhanced Immunotherapy against Cancer. J. Nanobiotechnology19 (1), 449. 10.1186/s12951-021-01202-x
7
ChenX.LiuY.WangL.LiuY.ZhangW.FanB.et al (2014). Enhanced Humoral and Cell-Mediated Immune Responses Generated by Cationic Polymer-Coated PLA Microspheres with Adsorbed HBsAg. Mol. Pharm.11 (6), 1772–1784. 10.1021/mp400597z
8
Da SilvaC. G.CampsM. G. M.LiT. M. W. Y.ChanA. B.OssendorpF.CruzL. J. (2019). Co-delivery of Immunomodulators in Biodegradable Nanoparticles Improves Therapeutic Efficacy of Cancer Vaccines. Biomaterials220, 119417. 10.1016/j.biomaterials.2019.119417
9
GouS.LiuW.WangS.ChenG.ChenZ.QiuL.et al (2021). Engineered Nanovaccine Targeting Clec9a+ Dendritic Cells Remarkably Enhances the Cancer Immunotherapy Effects of STING Agonist. Nano Lett.21 (23), 9939–9950. 10.1021/acs.nanolett.1c03243
10
HanS.MaW.JiangD.SutherlinL.ZhangJ.LuY.et al (2021). Intracellular Signaling Pathway in Dendritic Cells and Antigen Transport Pathway In Vivo Mediated by an OVA@DDAB/PLGA Nano-Vaccine. J. Nanobiotechnology19 (1), 394. 10.1186/s12951-021-01116-8
11
HaoJ.ChenJ.WangM.ZhaoJ.WangJ.WangX.et al (2020). Neutrophils, as “Trojan Horses”, Participate in the Delivery of Therapeutical PLGA Nanoparticles into a Tumor Based on the Chemotactic Effect, Participate in the Delivery of Therapeutical PLGA Nanoparticles into a Tumor Based on the Chemotactic Effect. Drug Deliv.27 (1), 1–14. 10.1080/10717544.2019.1701141
12
JavadK. F.SamiraJ.AliE. M. (2015). A Review of Molecular Mechanisms Involved in Toxicity of Nanoparticles. Adv. Pharm. Bull.5 (4), 447–454. 10.15171/apb.2015.061
13
KimH.NiuL.LarsonP.KucabaT. A.MurphyK. A.JamesB. R.et al (2018a). Polymeric Nanoparticles Encapsulating Novel TLR7/8 Agonists as Immunostimulatory Adjuvants for Enhanced Cancer Immunotherapy. Biomaterials164, 38–53. 10.1016/j.biomaterials.2018.02.034
14
KimH.SehgalD.KucabaT. A.FergusonD. M.GriffithT. S.PanyamJ. (2018b). Acidic pH-Responsive Polymer Nanoparticles as a TLR7/8 Agonist Delivery Platform for Cancer Immunotherapy. Nanoscale10 (44), 20851–20862. 10.1039/C8NR07201A
15
KoernerJ.HorvathD.HerrmannV. L.MacKerracherA.GanderB.YagitaH.et al (2021). PLGA-Particle Vaccine Carrying TLR3/RIG-I Ligand Riboxxim Synergizes with Immune Checkpoint Blockade for Effective Anti-cancer Immunotherapy. Nat. Commun.12 (1), 2935. 10.1038/s41467-021-23244-3
16
KohnepoushiC.NejatiV.DelirezhN.BiparvaP. (2019). Poly Lactic-Co-Glycolic Acid Nanoparticles Containing Human Gastric Tumor Lysates as Antigen Delivery Vehicles for Dendritic Cell-Based Antitumor Immunotherapy. Immunol. Investig.48 (8), 794–808. 10.1080/08820139.2019.1610889
17
LiS.FengX.WangJ.HeL.WangC.DingJ.et al (2018). Polymer Nanoparticles as Adjuvants in Cancer Immunotherapy. Nano Res.11 (11), 5769–5786. 10.1007/s12274-018-2124-7
18
LiuH.MiaoZ.ZhaZ. (2022). Cell Membrane-Coated Nanoparticles for Immunotherapy. Chin. Chem. Lett.33 (4), 1673–1680. 10.1016/j.cclet.2021.10.057
19
LiuJ.LiuX.HanY.ZhangJ.LiuD.MaG.et al (2018). Nanovaccine Incorporated with Hydroxychloroquine Enhances Antigen Cross-Presentation and Promotes Antitumor Immune Responses. ACS Appl. Mat. Interfaces10 (37), 30983–30993. 10.1021/acsami.8b09348
20
LiuW.-L.ZouM.-Z.QinS.-Y.ChengY.-J.MaY.-H.SunY.-X.et al (2020). Recent Advances of Cell Membrane-Coated Nanomaterials for Biomedical Applications. Adv. Funct. Mat.30 (39), 2003559. 10.1002/adfm.202003559
21
LuZ.-D.ChenY.-F.ShenS.XuC.-F.WangJ. (2021). Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy. ACS Appl. Mat. Interfaces13 (25), 29424–29438. 10.1021/acsami.1c08329
22
ParkW.GordonA. C.ChoS.HuangX.HarrisK. R.LarsonA. C.et al (2017). Immunomodulatory Magnetic Microspheres for Augmenting Tumor-specific Infiltration of Natural Killer (NK) Cells. ACS Appl. Mat. Interfaces9 (16), 13819–13824. 10.1021/acsami.7b02258
23
RezvantalabS.DrudeN. I.MoravejiM. K.GüvenerN.KoonsE. K.ShiY.et al (2018). PLGA-based Nanoparticles in Cancer Treatment. Front. Pharmacol.9, 1260. 10.3389/fphar.2018.01260
24
RochaC. V.GonçalvesV.da SilvaM. C.Bañobre-LópezM.GalloJ. (2022). PLGA-based Composites for Various Biomedical Applications. Int. J. Mol. Sci.23 (4), 2034. 10.3390/ijms23042034
25
RoointanA.KianpourS.MemariF.GandomaniM.Gheibi HayatS. M.Mohammadi-SamaniS. (2018). Poly(lactic-co-glycolic Acid): The Most Ardent and Flexible Candidate in Biomedicine. Int. J. Polym. Mater. Polym. Biomaterials67 (17), 1028–1049. 10.1080/00914037.2017.1405350
26
SwartzM. A.IidaN.RobertsE. W.SangalettiS.WongM. H.YullF. E.et al (2012). Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy. Cancer Res.72 (10), 2473–2480. 10.1158/0008-5472.Can-12-0122
27
ThakurN.ThakurS.ChatterjeeS.DasJ.SilP. C. (2020). Nanoparticles as Smart Carriers for Enhanced Cancer Immunotherapy. Front. Chem.8, 597806. 10.3389/fchem.2020.597806
28
VasirJ. K.LabhasetwarV. (2007). Biodegradable Nanoparticles for Cytosolic Delivery of Therapeutics. Adv. Drug Deliv. Rev.59 (8), 718–728. 10.1016/j.addr.2007.06.003
29
WhitesideT. L. (2008). The Tumor Microenvironment and its Role in Promoting Tumor Growth. Oncogene27 (45), 5904–5912. 10.1038/onc.2008.271
30
YangJ.AryaS.LungP.LinQ.HuangJ.LiQ. (2019). Hybrid Nanovaccine for the Co-delivery of the mRNA Antigen and Adjuvant. Nanoscale11 (45), 21782–21789. 10.1039/C9NR05475H
31
YangR.XuJ.XuL.SunX.ChenQ.ZhaoY.et al (2018). Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination. ACS Nano12 (6), 5121–5129. 10.1021/acsnano.7b09041
32
ZhangQ.HuangW.YuanM.LiW.HuaL.YangZ.et al (2020). Employing ATP as a New Adjuvant Promotes the Induction of Robust Antitumor Cellular Immunity by a PLGA Nanoparticle Vaccine. ACS Appl. Mat. Interfaces12 (49), 54399–54414. 10.1021/acsami.0c15522
33
ZhangR.BillingsleyM. M.MitchellM. J. (2018). Biomaterials for Vaccine-Based Cancer Immunotherapy. J. Control. Release292, 256–276. 10.1016/j.jconrel.2018.10.008
34
ZhangY.ChenY.LiJ.ZhuX.LiuY.WangX.et al (2021). Development of Toll-like Receptor Agonist-Loaded Nanoparticles as Precision Immunotherapy for Reprogramming Tumor-Associated Macrophages. ACS Appl. Mat. Interfaces13 (21), 24442–24452. 10.1021/acsami.1c01453
35
ZhouS.HuangY.ChenY.LiuS.XuM.JiangT.et al (2020). Engineering ApoE3-Incorporated Biomimetic Nanoparticle for Efficient Vaccine Delivery to Dendritic Cells via Macropinocytosis to Enhance Cancer Immunotherapy. Biomaterials235, 119795. 10.1016/j.biomaterials.2020.119795
Summary
Keywords
PLGA, immunotherapy, adjuvants, antigens, cancer, nanoparticles, drug delivery
Citation
Gao L, Li J and Song T (2022) Poly lactic-co-glycolic acid-based nanoparticles as delivery systems for enhanced cancer immunotherapy. Front. Chem. 10:973666. doi: 10.3389/fchem.2022.973666
Received
20 June 2022
Accepted
19 July 2022
Published
15 August 2022
Volume
10 - 2022
Edited by
Fan Huang, China Academy of Chinese Medical Sciences, China
Reviewed by
Zhanzhan Zhang, Tianjin Medical University, China
Jun Li, Hong Kong University of Science and Technology, Hong Kong SAR, China
Updates
Copyright
© 2022 Gao, Li and Song.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lei Gao, gl1185217391@163.com; Jing Li, 825418324@qq.com
This article was submitted to Nanoscience, a section of the journal Frontiers in Chemistry
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.